Biopharma M&A
Recent deal announcements covering the last 60 days. Deal activity continues to be strong, led by Pfizer’s winning $14 billion bid for Medivation over the likes of Sanofi and Gilead. Biopharma M&A
Nivolumad Therapy in Kidney Cancer
The use of nivolumab improved 4- and 5-year overall survival three-fold in patients with kidney cancer, according to data presented at the ASCO Annual Meeting. This is terrific for patients of this difficult disease, as well as for Bristol-Meyers Squibb who markets Optivo. Nivolumad therapy in kidney cancer